ETNB NASDAQ
89bio, Inc.
1W: +0.3%
1M: +1.0%
3M: +62.0%
1Y: +85.0%
3Y: +69.8%
5Y: -39.3%
$14.84
Last traded 2025-10-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.2B
52W Range4.16-15.06
Volume38,511,212
Avg Volume5,393,196
Beta1.26
Dividend—
Analyst Ratings
Company Info
CEORohan Palekar
Employees93
SectorHealthcare
IndustryBiotechnology
IPO Date2019-11-11
Website89bio.com
142 Sansome Street
San Francisco, CA 94104
US
San Francisco, CA 94104
US
415 432 9270
About 89bio, Inc.
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | D-Return | 45,150 | $9.98 | 2025-10-30 |
| RA CAPITAL MANAGEMEN | D-Return | 12,500 | $24.16 | 2025-10-30 |
| RA CAPITAL MANAGEMEN | D-Return | 56,400 | $9.60 | 2025-10-30 |
| RA CAPITAL MANAGEMEN | D-Return | 7,000 | $21.40 | 2025-10-30 |
| RA CAPITAL MANAGEMEN | D-Return | 7,000 | $24.29 | 2025-10-30 |